ArticleFrontiers in microbiology2016
Cytosolic Proteome Profiling of Aminoglycosides Resistant
Article in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Understanding bacterial biofilms: From definition to treatment strategies.Frontiers in cellular and infection microbiology · 2023Pooled it
- Application of MALDI-TOF MS to rapid identification of anaerobic bacteria.BMC infectious diseases · 2019Pooled it
- Diagnostic performance of nucleic acid MALDI-TOF MS in mycobacterial detection, species identification, and drug resistance testing for Mycobacterium tuberculosis.BMC infectious diseases · 2026Article
- Machine learning method for the prediction of Bedaquiline-resistantLife science alliance · 2026Article
- Proteomic Analysis of Drug-Resistant Mycobacterium tuberculosis Clinical Isolates Under Aminoglycoside Drug Pressure.Current microbiology · 2025Article
- Genomic characterization of multidrug-resistant tuberculosis in Shanghai, China: antibiotic resistance, virulence and transmission.JAC-antimicrobial resistance · 2025Article
- Metabolomic Profiling of the Responses of Planktonic and BiofilmAntibiotics (Basel, Switzerland) · 2022Article
- Low Rate of Acquired Linezolid Resistance in Multidrug-Resistant Tuberculosis Treated With Bedaquiline-Linezolid Combination.Frontiers in microbiology · 2021Article
- Identification of Potential Binders ofFrontiers in molecular biosciences · 2021Article
- Promising Lead Compounds in the Development of Potential Clinical Drug Candidate for Drug-Resistant Tuberculosis.Molecules (Basel, Switzerland) · 2020Review
- Metformin as Host-Directed Therapy for TB Treatment: Scoping Review.Frontiers in microbiology · 2020Article
- Simple Assay for Detection of the Central Asia Outbreak Clade of the Mycobacterium tuberculosis Beijing Genotype.Journal of clinical microbiology · 2019Article
- Antibiotics versus biofilm: an emerging battleground in microbial communities.Antimicrobial resistance and infection control · 2019Review
- Potential Alternative Strategy against Drug Resistant Tuberculosis: A Proteomics Prospect.Proteomes · 2018Review
- Cure of tuberculosis using nanotechnology: An overview.Journal of microbiology (Seoul, Korea) · 2018Review
- Article
- Repurposing and Revival of the Drugs: A New Approach to Combat the Drug Resistant Tuberculosis.Frontiers in microbiology · 2017Article
- Identification of Trombospondin-1 as a Novel Amelogenin Interactor by Functional Proteomics.Frontiers in chemistry · 2017Article
- Role of Bacterioferritin & Ferritin inFrontiers in cellular and infection microbiology · 2017Article
- Comparative Proteomics Analysis of Human Macrophages Infected with VirulentFrontiers in cellular and infection microbiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emergence of extensively drug resistant tuberculosis (XDR-TB) is the consequence of the failure of second line TB treatment. Aminoglycosides are the important second line anti-TB drugs used to treat the multi drug resistant tuberculosis (MDR-TB). Main known mechanism of action of aminoglycosides is to inhibit the protein synthesis by inhibiting the normal functioning of ribosome. Primary target of aminoglycosides are the ribosomal RNA and its associated proteins. Various mechanisms have been proposed for aminoglycosides resistance but still some are unsolved. As proteins are involved in most of the biological processes, these act as a potential diagnostic markers and drug targets. In the present study we analyzed the purely cytosolic proteome of amikacin (AK) and kanamycin (KM) resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.